Alico (ALCO) Q2 2024: $28.5M Inventory Write-Down Sharpens Focus on Citrus Recovery and Land Monetization

May 7, 2024 | By EarningsIQ Research

Alico’s second quarter exposed the persistent operational drag from Hurricane Ian, driving a $28.5 million inventory write-down and highlighting the slow pace of citrus recovery. Management is doubling down on trunk-injection therapies and land monetization to offset weak production, while signaling confidence in multi-year contract renewals at higher pricing. Investors must weigh near-term volatility against the company’s strategic pivot toward asset optimization and improved citrus yields.

Summary

• Inventory Reset Drives Urgency: $28.5 million inventory write-down underscores the depth of citrus production challenges.
• Land Monetization Accelerates: Asset sales and leasebacks are being used to redeploy capital from underperforming groves.
• Citrus Therapy Scale-Up: Doubling trunk-injection treatments signals a multi-year commitment to yield recovery.

Business Overview

Alico is a vertically integrated agribusiness specializing in citrus production and land management in Florida. The company generates revenue primarily from selling citrus fruit under multi-year contracts to processors like Tropicana, and from providing grove management services to third parties. Alico also monetizes real estate assets through sales, leasebacks, and strategic land use transitions, with citrus operations representing the core of its business model.

Performance Analysis

Revenue for the quarter declined 14.9% year-over-year, primarily reflecting delayed Valencia harvest timing and lower volumes, as the company continued to grapple with lingering impacts from Hurricane Ian. While an increase in average price per pound solid and new grove management contracts provided some offset, the operational headwinds culminated in a $28.5 million inventory write-down and increased operating expenses. The absence of prior-year crop insurance proceeds further magnified the loss, with the quarter closing at a net loss attributable to common shareholders of $15.8 million.

On a six-month basis, total revenue was up slightly due to favorable pricing and expanded management services, but these gains were overshadowed by higher operating costs and the absence of insurance recoveries. Notably, the company posted a net income for the half, driven by a $74.9 million gain on a large land sale to the State of Florida, illustrating the increasing importance of asset monetization in the financial mix.

• Production Disruption Persists: Fruit drop and quality issues continued to limit volume, with early and mid-season crop yields below expectations.
• Cost Base Under Pressure: Operating expenses rose sharply as insurance offsets disappeared and inventory adjustments took hold.
• Land Sales Bolster Results: Significant gains from real estate transactions masked underlying citrus weakness on a year-to-date basis.

The financial picture remains highly sensitive to citrus recovery timelines and the pace of asset monetization, with near-term profitability dependent on both operational execution and opportunistic land transactions.

Executive Commentary

Strategic Positioning

1. Citrus Therapy and Yield Recovery

Alico’s core operational bet is on oxytetracycline (OTC) trunk injection, a therapy targeting citrus greening disease. After initial application to 35% of trees in 2023, the company is doubling treatment coverage for the next harvest. Early results showed yield improvement versus control groups, though quality and juice content gains remain elusive. Management is positioning this as a multi-year solution, with hopes for sequential improvement as more trees are treated.

2. Contract Pricing Reset

Multi-year contracts with major offtakers like Tropicana are expiring, and management is targeting renewals at higher prices per pound solid. This reflects broader market tightness and is intended to offset volume shortfalls. The outcome of these negotiations will directly impact revenue stability and pricing power in future periods.

3. Land Monetization and Asset Redeployment

Non-core and underperforming groves are being transitioned to alternative uses or sold outright. Recent transactions include a pending $7 million land sale and a purchase option agreement for nearly 900 acres at $11,500 per acre. In some deals, Alico retains the right to lease back citrus acreage at minimal cost, preserving operational flexibility while unlocking capital for higher-return uses.

4. Balance Sheet and Liquidity Stewardship

With $95 million in undrawn credit lines and proceeds from land sales, liquidity is not an immediate concern despite operational losses. Management is maintaining a conservative posture on net debt guidance due to ongoing impairments and the unpredictable timing of asset sales, but stresses that capital resources are sufficient to fund recovery and repositioning efforts.

5. Active Land Management Optionality

Beyond citrus, Alico is evaluating the highest and best use for all properties, including mining and third-party leasing. This diversified approach is intended to provide investors with both agricultural stability and the upside of land value appreciation, positioning the company as both a citrus operator and a land management platform.

Key Considerations

This quarter’s results highlight a company at an operational and strategic crossroads, balancing the slow grind of citrus recovery with the near-term financial lift from land sales. The interplay between biological timelines, contract pricing, and asset monetization will determine the shape of future earnings power.

Key Considerations:

• Therapy Execution Risk: Full benefits from OTC trunk injection may take multiple seasons to materialize, and initial quality gains have not yet emerged.
• Contract Renegotiation Stakes: Success in securing higher pricing on new multi-year agreements is critical for margin restoration.
• Land Sale Timing and Valuation: Monetization of non-core assets is supporting near-term liquidity, but depends on favorable market demand and regulatory approvals.
• Cost Control and Insurance Tailwinds: Absence of insurance proceeds and rising employee costs have pressured margins, requiring disciplined expense management.
• Balance Sheet Flexibility: Ample credit lines and sale proceeds provide a buffer, but persistent operational losses could erode this position if recovery lags.

Risks

Alico faces material risks from continued citrus production volatility, biological disease pressure, and the uncertain pace of asset sales. Delays in contract renewals or regulatory hurdles for land transactions could amplify liquidity and earnings pressure. The company’s reliance on a few large customers for citrus sales concentrates commercial risk, while the biological nature of recovery efforts introduces execution uncertainty that could persist for multiple seasons.

Forward Outlook

For the next quarter, Alico did not provide explicit quantitative guidance but signaled:

• Ongoing expansion of OTC trunk injection therapy to nearly all producing trees
• Expectation of “significant increase” in fruit harvested next season as recovery progresses

For full-year 2024, management did not update guidance, citing uncertainty around impairments and land sale timing. They highlighted:

• Pending multi-year contract renewals at higher pricing levels
• Continued evaluation and monetization of underperforming groves

Management emphasized that steady liquidity, active land management, and therapy scale-up are expected to support improved results as the business moves further from the impact of Hurricane Ian.

Takeaways

Alico’s Q2 marks a pivotal period of operational reset and strategic adaptation, as the company pursues long-term citrus recovery while monetizing land to bridge near-term financial gaps.

• Inventory Write-Down Signals Depth of Operational Challenge: The $28.5 million adjustment reflects both biological headwinds and the urgency of therapy interventions, setting a low base for future recovery.
• Asset Monetization Provides Financial Cushion: Gains from land sales are masking operational losses, but are finite and dependent on execution.
• Multi-Year Recovery Hinges on Therapy, Pricing, and Diversification: Investors should monitor the pace of yield improvement, contract renewals, and the evolution of the land management strategy in coming quarters.

Conclusion

Alico’s second quarter underscores the twin imperatives of operational turnaround and asset optimization. While biological recovery in citrus is inherently slow, management’s aggressive therapy expansion and land monetization efforts provide both optionality and downside protection. The next twelve months will be critical in validating the durability of these strategies and restoring earnings power.

Industry Read-Through

Alico’s results reinforce the ongoing volatility and biological risk facing the Florida citrus sector, with disease management and weather recovery timelines extending beyond initial expectations. The company’s pivot toward land monetization and diversified property use highlights a broader trend among agricultural operators to unlock value from non-core assets, especially in markets where crop yields remain unpredictable. For industry peers, the experience with trunk-injection therapies and contract repricing may shape future negotiations and investment in disease mitigation. Investors in agricultural and land-rich businesses should closely watch the interplay between biological recovery cycles and asset management strategies as a template for navigating extended operational headwinds.

ALCO Consumer Staples Agriculture Land Management Citrus Asset Monetization Hurricane Recovery Contract Pricing